J&J sues Mylan over Zytiga patent; NICE cracks down on antibiotics overuse; Kythera submits double-chin med for EU approval;

@FiercePharma: ICYMI yesterday: Will docs jump on new biosims? Survey shows they'll need some nudging. More | Follow @FiercePharma

@EricPFierce: Xellia decides it's best to have U.S. sales operations next to Raleigh, NC, plant it's expanding. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Mylan hopes Disney can add new magic to its allergy-fighting kingdom. FiercePharmaMarketing story | Follow @CarlyHFierce

> Generics-maker Mylan ($MYL) confirmed that it had been sued by Johnson & Johnson's ($JNJ) Janssen unit for patent infringement, over its branded cancer drug Zytiga. Release

> The National Institute for Health and Care Excellence (NICE) issued new guidelines designed to crack down on overuse of antibiotics to combat resistance to the meds. Report

> Kythera Biopharmaceuticals, which is about to be acquired by Allergan ($AGN), asked European regulators to approve its double-chin injection, approved in the U.S. as Kybella. Release

> AMAG Pharmaceuticals ($AMAG) wrapped up its $700 million buyout of Cord Blood Registry. Release

Medical Device News

@FierceMedDev: UPDATED with comment from Fujifilm: FDA slaps three duodenoscope manufacturers with warning letters. Article | Follow @FierceMedDev

@EmilyWFierce: San Diego's Genalyte reeled in $44M in a Series C round for its microchip testing platform. Release | Follow @EmilyWFierce

> WSJ: New devices for rectal cancer surgery reduce need for colostomies. Story

> Illumina, LabCorp, Mayo Clinic, Warburg assemble to back latest consumer genomics entrant: Helix. Article

> FDA slaps three duodenoscope manufacturers with warning letters over related devices. Report

Biotech News

@FierceBiotech: ICYMI: Kite CEO Arie Belldegrun has a simple message for investors this morning: Relax. Story | Follow @FierceBiotech

@JohnCFierce: No surprise, coming off a $70M crossover, RegenX Bio files $100M. S-1/Report | Follow @JohnCFierce

> Omeros soars on fresh promise for its rare disease treatment. More

> Wave LifeSci banks $66M with a 'pure' take on synthetic chemistry. Story

> Edge Therapeutics swings for a $115M IPO with eyes on Phase III. Article

> Esperion surges after FDA offers a shot at quick approval for LDL-lowering drug. Report

Drug Delivery News

> BioDelivery snags new FDA approval for Onsolis after ditching Meda partnership. More

> Hydrogels: Study shows use in ulcerative colitis and Army invests in wound healing research. Report

> Checkmate Pharma gets $20M in Series A to develop cancer candidate with VLP platform. Story

> Cannabics Pharma's extended-release medical marijuana capsules available in Colorado. Item

> Intersect's steroid-releasing implant meets its endpoint in bid for expanded indication. Article

Pharma Manufacturing News

> FDA castigates three Mylan sterile drug plants in warning letter. News

> Hemispherx says plant upgrade will allow it to return its genital wart treatment to market. Item

> GSK resumes production at plant where Legionella bacteria was detected. Report

> Merck manufacturing shedding another 2,600 jobs. Story

> Novo Nordisk looks at building its first U.S. insulin plant. Article

Pharma Asia News

> More scrutiny for Japanese duodenoscope makers on notification failures. Report

> India's Lee Pharma turned down on CL challenge to AZ's Onglyza. Item

> Does China yuan devaluation mean more downbeat pharma earnings? Article

> Japan's Mitsui buys stake in India top drug wholesaler Keimed. Story

> Going private for WuXi PharmaTech opens dealmaking options. More

And Finally... After recalling all its frozen desserts amid a deadly listeria outbreak, Blue Bell Creamery says it's ready to start selling ice cream again. Report

Suggested Articles

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan

Pfizer struck a deal to produce Gilead Sciences' remdesivir, which has been running short at some hard-hit U.S. hospitals.